|
市場調查報告書
新的技術:幹細胞
Emerging Technologies: Stem cells
| 出版商 |
Datamonitor |
| 出版日期 |
2011年11月 |
商品編碼 |
229453 |
| 內容資訊 |
英文 Pages: 61 |
| 價格 |
|
|
新的技術:幹細胞 是由出版商Datamonitor在2011年11月所出版的。
這份英文市場調查報告書包含Pages: 61 價格從美金3800起跳。
本報告提供今後將更具重要性的幹細胞所扮演的角色相關調查分析，彙整各治療領域上的前臨床階段到登記候補藥之間的開發管道及主要企業的趨勢等資料，概述為以下內容。
目錄
第1章 摘要整理
第2章 關於本調查報告書
- PharmaVitae Explorer資料庫
- 各章節
- 資料來源
第3章 簡介
第4章 幹細胞的平台
- 主要調查結果
- 幹細胞平台相關概況
- 心血管系
- 中樞神經系統
- 眼科
- 內分泌與代謝異常
- 免疫系疾病和炎症
- 肌肉骨骼系
- 其他的適應症
第5章 主要企業
第6章 附錄
Description
Introduction
Stem cell therapies will play an increasingly important role in the underserved field of regenerative medicine, as preclinical discoveries are translated into the clinical setting and product candidates slowly progress through a diverse pipeline.
Features and benefits
- A full stem cell pipeline by each therapeutic category from preclinical stage to registration candidates.
- Provides an insight into key players, recent deals and developments.
Highlights
- Small and medium-sized research-led companies dominate the stem cells landscape, with a few large pharmaceutical companies beginning to invest in recent years. The stem cells sector is highly heterogeneous, consisting of different technology platforms, including embryonic and adult stem cells, applied in a wide range of therapy areas.
- Geron's recent divestment in the sector highlights the several technical challenges associated with the application of stem cells in certain therapy areas, in particular, the central nervous system.
Your key questions answered
- Assess the key challenges and opportunities expected to shape the sector in the near term.
- Benchmark the competitive landscape within the stem cell sector, identifying the key pipeline candidates and most active disease areas of development.
TOC
Executive Summary
- Strategic scoping and focus
- Datamonitor key findings
- Recent updates
ABOUT THIS REPORT
- PharmaVitae Explorer database
- Chapter structure
- Introduction to stem cells
- Stem cell pipeline
- Key players
- Data sourcing
INTRODUCTION TO STEM CELLS
- Key findings
- An introduction to stem cells
- Types of stem cells
- Pipeline snapshotAlthough bone marrow stem cell transplant has been routinely used for over 4 decades to treat hematological malignancies, the potential of stem cells to regenerate or replace highly specialized damaged or lost tissues in serious degenerative disorders or debilitating diseases, such as myocardial infarction, spinal cord injuries, ischemic stroke, macular degeneration, diabetes, and multiple sclerosis, has yet to be realized. Key limitations that still need to be addressed include successful delivery, differentiation, engraftment, integration, vascularization, functionality, and long-term safety of the transplanted cells. In view of this, several companies are currently exploiting more easily achievable goals, using a more drug-like approach that utilizes stem cells to alter physiological conditions within the damaged tissue and that indirectly promotes repair and regulates inflammatory and immunomodulatory pathways.
- SWOT analysis
- Strengths
- Opportunities
- Weaknesses
- Threats
STEM CELL PIPELINE
- Key findings
- Stem cell pipeline overview
- Cardiovascular
- Central nervous system
- Ophthalmology
- Endocrine and metabolic disorders
- Immunology and inflammation
- Musculoskeletal
- Other indications
THE KEY PLAYERS
- Overview
- Mesoblast
- Osiris Therapeutics
- Athersys
- Gamida Cell
- Cytori Therapeutics
- Geron
APPENDIX
- References
- Datamonitor research
- Journal papers
- Exchange rates
|
